10 completed, 3 recruiting, 1 terminated, 1 unknown. 15 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 10, Recruiting 3, Terminated 1, Unknown 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Universiteit Antwerpen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Targeting Muscle Strength Loss Due to Hospitalization in Older Adults by Blood-flow Restriction Combined With an Electromyography-driven Serious Game. Gamified isometric strength training with blood flow restriction, Standard Physiotherapy - Hospital Associated Disability, Immobility | Phase 2 | Recruiting | Vrije Universiteit Brussel | 120 | 2026-06-05 | 2026-11-02 |
| Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination Gardasil 9 (2 dose regimen) - Human Papilloma Virus Infection Type 16 | Phase 2 | Recruiting | Universiteit Antwerpen | 50 | 2026-03-25 | 2026-03-27 |
| Comparative Study of the Effects of Dry Needling and Botulinum Toxin Type A as a Treatment for Lower Limb Post-stroke Spasticity Botulinum toxin type A, Dry Needling - Stroke | Phase 2 / Phase 3 | Recruiting | Universiteit Antwerpen | 90 | 2024-09-01 | 2026-05-04 |
| Effects of Exercise During the Acute Phase of Burns Exercise, Standard of Care - Burns | Phase 2 | Unknown | Universiteit Antwerpen | 40 | 2020-05-04 | 2020-08-14 |
| Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola Ad26.ZEBOV vaccine - Ebola Virus Disease | Phase 2 | Completed | Universiteit Antwerpen | 699 | 2019-12-18 | 2026-07-14 |
| A Study to Assess the Efficacy of Omnivirol-Salicylic Acid Combination Therapy for Cutaneous Warts With Emphasis on Persistent Warts AV2-SA2, SA - Cutaneous Warts | Phase 2 / Phase 3 | Completed | Universiteit Antwerpen | 260 | 2018-01-01 | 2023-05-17 |
| Pacing Activity Self-management for Patients With Multiple Sclerosis pacing, relaxation - Multiple Sclerosis | Phase 2 | Completed | Vrije Universiteit Brussel | 31 | 2011-10-01 | 2015-12-17 |
| Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome Pacing, relaxation therapy - Chronic Fatigue Syndrome | Phase 2 | Completed | Vrije Universiteit Brussel | 33 | 2011-08-01 | 2015-12-17 |
| Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer chemotherapy - Colorectal Cancer | Phase 2 | Completed | Jules Bordet Institute | 97 | 2011-02-01 | 2016-02-24 |
| MSC and HSC Coinfusion in Mismatched Minitransplants Mesenchymal stem cells, Isotonic solution - Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute | Phase 2 | Terminated | University of Liege | 39 | 2010-07-01 | 2021-09-08 |
| Evaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC) combination chemotherapy (pemetrexed + cisplatin), thoracic irradiation + pemetrexed - Non-Small Cell Lung Cancer | Phase 2 | Completed | University Hospital, Antwerp | 30 | 2006-02-01 | 2009-04-10 |
| Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer cisplatin/docetaxel, cisplatin/vinorelbine - Non-small Cell Lung Cancer | Phase 2 | Completed | University Hospital, Antwerp | 99 | 2005-12-01 | 2010-11-30 |
| Evaluation of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation for Non-resectable Stage III NSCLC carboplatin/gemcitabine, cisplatin/radiation therapy - Non-Small-Cell-Lung Cancer | Phase 2 | Completed | University Hospital, Antwerp | 77 | 2003-01-01 | 2013-07-12 |
| Beta-Cell Transplantation in Pre-Uremic Patients With Type 1 Diabetes islet cell grafts - Diabetes Mellitus, Type 1 | Phase 1 / Phase 2 | Completed | Universitair Ziekenhuis Brussel | 36 | 2000-09-01 | 2008-02-26 |
| Extension of Phase II Therapeutic Trial With a Humanized Non-Mitogenic CD3 (ChAgly CD3) Monoclonal Antibody in Recently Diagnosed Type 1 Diabetic Patients ChAgly CD3, Placebo - Diabetes Mellitus, Type 1 | Phase 2 | Completed | Universitair Ziekenhuis Brussel | 80 | 2000-06-01 | 2008-09-29 |
Carcinoma, Non-Small-Cell Lung (3) · Diabetes Mellitus, Type 1 (2) · Lung Neoplasms (2) · Burns (1) · Colorectal Neoplasms (1) · Fatigue Syndrome, Chronic (1) · Hemorrhagic Fever, Ebola (1) · Hodgkin Disease (1) · Insulin Resistance (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Multiple Sclerosis (1)
Cisplatin (3) · Standard of Care (2) · Botulinum Toxins, Type A (1) · Capecitabine (1) · Carboplatin (1) · Clinical Protocols (1) · Docetaxel (1) · Drug Therapy (1) · Drug Therapy, Combination (1) · Dry Needling (1) · Exercise (1) · Gemcitabine (1) · Human Papillomavirus Recombinant Vaccine nonavalent (1) · Isotonic Solutions (1) · Pemetrexed (1)
Belgium (14) · Canada (1) · Democratic Republic of the Congo (1) · Germany (1) · Spain (1)
Daphne Kos, PhD (2) · Alain Hendlisz, MD (1) · Augustin Ferrant, MD, PhD (1) · Bart Keymeulen, MD, PhD (1) · Bart Keymeulen, MD,PhD (1) · Carlos Graux, MD, PhD (1) · Chantal Doyen, MD, PhD (1) · Chantal Lechanteur, PhD (1) · Dominik Selleslag, MD, PhD (1) · Dominique Bron, MD, PhD (1) · Etienne Baudoux, MD (1) · Eva Swinnen, prof. dr. (1) · Evelyne Willems, MD (1) · Hypolite Mavoko Muhindo, Dr. (1)
PMID 11395204, PMID 14741143, PMID 17090674, PMID 17548132, PMID 17553602, PMID 18560516, PMID 20225393, PMID 22342706, PMID 23125444, PMID 23170176, PMID 24738640, PMID 25816051, PMID 26421426, PMID 27779572, PMID 29679103, PMID 30239838, PMID 30744591, PMID 32433237, PMID 34378545, PMID 34588237, PMID 35550847, PMID 37840107, PMID 37993355, PMID 38552653, PMID 39697147, PMID 42160369
2025 (1)